{"id":4049,"date":"2021-01-26T08:50:00","date_gmt":"2021-01-26T08:50:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-notice-of-allowance-for-patentansokan-i-kanada\/"},"modified":"2021-01-26T08:50:00","modified_gmt":"2021-01-26T08:50:00","slug":"nanexa-erhaller-notice-of-allowance-for-patentansokan-i-kanada","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-erhaller-notice-of-allowance-for-patentansokan-i-kanada\/","title":{"rendered":"Nanexa erh\u00e5ller Notice of Allowance f\u00f6r patentans\u00f6kan i Kanada"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Nanexa AB (publ) meddelade idag att bolaget har mottagit en s\u00e5 kallad \u201dNotice of Allowance\u201d f\u00f6r en patentans\u00f6kan i Kanada. Patentans\u00f6kan avser PharmaShell\u00ae f\u00f6r administrering p\u00e5 alla t\u00e4nkbara s\u00e4tt, t ex genom parenteral injektion, inhalation och genom orala beredningar.<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>\u201dDet \u00e4r mycket gl\u00e4djande att v\u00e5rt kontinuerliga arbete med patentportf\u00f6ljen ger resultat och ett patent i Kanada kommer \u00f6ka marknaden f\u00f6r oss ytterligare. Patentprocessen fortl\u00f6per \u00e4ven i andra l\u00e4nder och jag bed\u00f6mer att vi kan f\u00e5 fler godk\u00e4nnanden\u00a0av v\u00e5ra patentans\u00f6kningar under \u00e5ret\u201d, s\u00e4ger David Westberg, vd f\u00f6r Nanexa.<\/p>\n<p>En Notice of Allowance tillk\u00e4nnager att patentans\u00f6kan nu anses vara redo f\u00f6r godk\u00e4nnande. Processen p\u00e5g\u00e5r dock fortfarande och det \u00e4r i dagsl\u00e4get inte m\u00f6jligt att f\u00f6rutse n\u00e4r patent beviljas.<br \/>\u00a0<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr \/>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" target=\"_blank\" rel=\"nofollow noopener\">david.westberg@nanexa.se<\/a><br \/><a href=\"http:\/\/www.nanexa.com\" target=\"_blank\" rel=\"nofollow noopener\">www.nanexa.com<\/a><\/p>\n<p>Erik Penser Bank \u00e4r bolagets Certified Adviser och n\u00e5s p\u00e5 08-463 83 00, e-post: certifiedadviser@penser.se<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr \/>\n<p>Nanexa AB \u00e4r ett nanoteknologiskt drug delivery-f\u00f6retag fokuserat p\u00e5 utvecklingen av PharmaShell\u00ae, ett nytt och banbrytande drug delivery-system med stor\u00a0potential inom ett flertal substanstyper och indikationsomr\u00e5den. Inom ramen f\u00f6r PharmaShell\u00ae utvecklar Nanexa egna projekt och har samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland\u00a0AstraZeneca.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-pdf\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/308f15d7-8e20-4b9b-88b3-33ae36971f73\/nanexa-erhaller-notice-of-allowance-for-patentansokan-i-kanada.pdf\" target=\"_blank\" rel=\"nofollow noopener\">Nanexa erh\u00e5ller Notice of Allowance f\u00f6r patentans\u00f6kan i Kanada<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nanexa AB (publ) meddelade idag att bolaget har mottagit en s\u00e5 kallad \u201dNotice of Allowance\u201d f\u00f6r en patentans\u00f6kan i Kanada. Patentans\u00f6kan avser PharmaShell\u00ae f\u00f6r administrering p\u00e5 alla t\u00e4nkbara s\u00e4tt, t ex genom parenteral injektion, inhalation och genom orala beredningar.<\/p>\n","protected":false},"template":"","class_list":["post-4049","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa erh\u00e5ller Notice of Allowance f\u00f6r patentans\u00f6kan i Kanada - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-notice-of-allowance-for-patentansokan-i-kanada\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa erh\u00e5ller Notice of Allowance f\u00f6r patentans\u00f6kan i Kanada - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa AB (publ) meddelade idag att bolaget har mottagit en s\u00e5 kallad \u201dNotice of Allowance\u201d f\u00f6r en patentans\u00f6kan i Kanada. Patentans\u00f6kan avser PharmaShell\u00ae f\u00f6r administrering p\u00e5 alla t\u00e4nkbara s\u00e4tt, t ex genom parenteral injektion, inhalation och genom orala beredningar.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-notice-of-allowance-for-patentansokan-i-kanada\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-erhaller-notice-of-allowance-for-patentansokan-i-kanada\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-erhaller-notice-of-allowance-for-patentansokan-i-kanada\\\/\",\"name\":\"Nanexa erh\u00e5ller Notice of Allowance f\u00f6r patentans\u00f6kan i Kanada - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2021-01-26T08:50:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-erhaller-notice-of-allowance-for-patentansokan-i-kanada\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-erhaller-notice-of-allowance-for-patentansokan-i-kanada\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-erhaller-notice-of-allowance-for-patentansokan-i-kanada\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa erh\u00e5ller Notice of Allowance f\u00f6r patentans\u00f6kan i Kanada\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa erh\u00e5ller Notice of Allowance f\u00f6r patentans\u00f6kan i Kanada - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-notice-of-allowance-for-patentansokan-i-kanada\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa erh\u00e5ller Notice of Allowance f\u00f6r patentans\u00f6kan i Kanada - Nanexa AB","og_description":"Nanexa AB (publ) meddelade idag att bolaget har mottagit en s\u00e5 kallad \u201dNotice of Allowance\u201d f\u00f6r en patentans\u00f6kan i Kanada. Patentans\u00f6kan avser PharmaShell\u00ae f\u00f6r administrering p\u00e5 alla t\u00e4nkbara s\u00e4tt, t ex genom parenteral injektion, inhalation och genom orala beredningar.","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-notice-of-allowance-for-patentansokan-i-kanada\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-notice-of-allowance-for-patentansokan-i-kanada\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-notice-of-allowance-for-patentansokan-i-kanada\/","name":"Nanexa erh\u00e5ller Notice of Allowance f\u00f6r patentans\u00f6kan i Kanada - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2021-01-26T08:50:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-notice-of-allowance-for-patentansokan-i-kanada\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-notice-of-allowance-for-patentansokan-i-kanada\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-notice-of-allowance-for-patentansokan-i-kanada\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa erh\u00e5ller Notice of Allowance f\u00f6r patentans\u00f6kan i Kanada"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/4049","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=4049"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}